مقایسه علائم مدل بیماری پارکینسون القا شده با روتنون در موشهای سوری نر

نوع مقاله: مقاله پژوهشی

نویسندگان

1 گروه زیست شناسی، دانشگاه شهید چمران اهواز، اهواز، ایران

2 گروه آمار، دانشگاه شهید چمران اهواز، اهواز، ایران

چکیده

بیماری پارکینسون (PD) به عنوان نوعی اختلال حرکتی در نظر گرفته می­شود، و تشخیص آن به وجود مجموعه­ای از علائم حرکتی اصلی وابسته است. با توجه به اینکه پاتوژنز بیماری پارکینسون تا امروز به خوبی درک نشده است، این امر اهمیت زیاد استفاده از مدل‌های جانوری را برای درک بهتر علت بیماری پارکینسون و کشف راه درمان آن مشخص می‌کند.  پژوهش حاضر با هدف ارائه شواهد جدید در رابطه با مقایسه تاثیرات روتنون بر علائم بیماری پارکینسون می­باشد. 30 عدد موش سوری نر ( 2±30 گرم) به طور تصادفی به سه گروه تقسیم شدند؛ گروه کنترل، گروه حلال روتنون و گروه روتنون (ROT). گروه روتنون به مدت 19 روز (2 میلی­گرم/ کیلوگرم/ 48 ساعت) روتنون دریافت کردند. پس از آن، علائم تعادل، حرکت، جمود عضلانی و قدرت عضلانی با آزمون­های روتارود، میدان-باز، بار تست و بار افقی سه­گانه مورد ارزیابی و به منظور مقایسه اثرات روتنون بر این علائم، نتایج با هم مقایسه شد. تجویز روتنون  قدرت عضلانی را در هر سه گروه نسبت به علائم دیگر بیشتر تحت تاثیر قرار داد (05/0p<). در درجه بعدی تعادل، حرکت و جمود عضلانی تحت تاثیر قرار گرفتند. روتنون توانست علائم مدل بیماری پارکینسون را تحت تاثیر قرار دهد که این تاثیر بر قدرت عضلانی بیشتر از دیگر علائم بود. احتمالاً این موضوع، از جمله ویژگی­های اصلی روتنون در ایجاد مدل تجربی بیماری پارکینسون باشد.

کلیدواژه‌ها


عنوان مقاله [English]

Comparing the Components between Parkinson's Disease Model in the Male Mice Induced by Rotenone

نویسندگان [English]

  • Mohammad Mohammad Ali Mansouri 1
  • Ahmad Ali Moazedi 1
  • Gholam Ali Parham 2
1 Department of Biology, Shahid Chamran University of Ahvaz, Ahvaz, Iran
2 Department of Statistics, Shahid Chamran University of Ahvaz, Ahvaz, Iran
چکیده [English]

Parkinson's disease (PD) is considered as a movement disorder, and its diagnosis is based on the presence of a set of cardinal motor symptoms. Since the pathogenesis of PD is not well understood today, the importance of the use of animal models to better understand PD and its cure is discovered. We aimed to provide new evidence on the comparison effect of rotenone on the components of PD. Thirty male mice (30±2 gr) were randomly divided into 3 groups; control group, rotenone solvent group, and rotenone group (ROT). ROT was treated with rotenone injections (2 mg/kg/48 h) for 19 days. Thus, the components of balance, movement, muscle rigidity and muscle strength tested by rotarod, open-field, and triple horizontal bar, and save testing data to evaluate and compare the effects of rotenone on these components. Component of muscle strength in all groups affected more than other components (P<0.05). In the next degree of balance, movement and muscle rigidity were affected. Rotenone could affect components of PD model which improved muscle strength component and was better than that of the other components. Probably this subject, including the main features of rotenone creates an experimental model of Parkinson's disease.

کلیدواژه‌ها [English]

  • Balance
  • Rotenone
  • Model of Parkinson's disease
  • Mice
  • Muscle rigidity
  • Muscle strength
1. Alexander G.E. 2004. Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues in Clinical Neuroscience, 6(3): 259-280.

2. Anchan B., Divya M. 2016. GPR30 Activation Decreases Anxiety in the Open Field Test but Not in the Elevated plus Maze Test in Female Mice. Brain and Behavior, 4(1): 51-59.

3. Annemieke A., Maaike V. 2014. Assessing Functional Performance in the Mdx Mouse Model. Journal of Visualized Experiments, 85: 51303.

4. Beitz J.M., 2014. Parkinson's disease: a review. Front Bioscience (Schol Ed), 6: 65-74.

5. Bertram L., Tanzi R.E., 2005. The genetic epidemiology of neurodegenerative disease. Journal of Clinical Investigation, 115(6): 1449-1457.

6. Cornforth D.P., 1985. Effect of Rotenone and pH on the Color of Pre-rigor Muscle, Utah Agricultural Experiment Station, 45(4): 463-472.

7. Dauer W., Przedborski S., 2003. Parkinson's disease: mechanisms and models. Neuron, 39(6): 889-909.

8. Eshraghi Jazi F., Alaei H., Azizi Malekabadi H., Pilehvarian A.A., Gharavi Naeini M., Ahmadi M.S., Shah-Mansouri E., Ciahmard Z., 2012. The Effects of Red Grape Juice and Exercise on Parkinson's Disease in Male Rats. Journal of Isfahan University of Medical Sciences, 2(2): 90-96.

9. Goetz C.G., 2011. The History of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies. Cold Spring Harbor Perspectives in Medicine, 1(1): a008862.

10. Hatami H, Dehghan G., 2016. The Effect of Ethanolic The effect of ethanolic extract of Saffron (Crocus sativus L.) on improving the spatial memory parameters in the experimental models of Parkinson disease in male rats. Journal of Fasa University of Medical Sciences, 5(4): 534-541

11. Hattori K., Uchino S., Isosaka T., Maekawa M., Iyo M., Sato T., Kohsaka S., Yagi T., Yuasa S., 2006. Fyn is required for haloperidol-induced catalepsy in mice. The Journal of Biological Chemistry, 281(11): 7129-7135.

12. Jankovic J., Stacy M., 2007. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. Central Nervous System Drugs, 21(8): 677-692.

13. Jin H., Arthi K., Anamitra G., 2014. Mitochondria-targeted antioxidants for treatment of Parkinson's disease: Preclinical and clinical outcomes. Biochimica et Biophysica Acta (BBA)- Molecular Basis of Disease, 1842(8): 1282-1294.

14. Ogawa N., 1994. Levodopa and dopamine agonists in the treatment of Parkinson’s disease: advantages and disadvantages. European Neurology, 34(Suppl. 3): 20-28.

15. Parameshwaran K., Irwin M.H., Steliou K., Pinkert C.A., 2012. Protection by an antioxidant of rotenone-induced neuromotor decline, reactive oxygen species generation and cellular stress in mouse brain. Pharmacology, Biochemistry and Behavior, 101(3): 487-492.

16. Rahimmi A., Khosrobakhsh F., Izadpanah E., Hassanzadeh K., 2014. Induction of Parkinson’s Disease Model in Rat by Rotenone. Journal of Isfahan University of Medical Sciences, 32(296): 1250-58.

17. Ramalingam R., Bindu M. B., Sujeevana K., 2014. AntiParkinson’s studies of ethanolic extract of  Leucas aspera in mice. World Journal of Pharmacy and Pharmaceutical Sciences, 3(7): 1226-1235.

18. Richter F., Hamann M., Richter A., 2007. Chronic rotenone treatment induces behavioral effects but no pathological signs of Parkinsonism in mice. Journal of Neuroscience Research, 85(3): 681-91.

19. Robert M.J., 2013. Deacon, measuring motor coordination in mice. Journal of Visulized Experiments, 75(2609): 1-8.

20. Sibi P., 2014. Effect of hydro-alcoholic root extract of Plumbago zeylanica on rotenone induced Parkinson diseases. International Journal of Research, Effect of hydro-alcoholic root extract of Plumbago zeylanica on rotenone induced Parkinson diseases. International Journal of Research, 5(4): 494-501.

21.Tolosa, E., Tolosa E.L., Martí M.J., Valldeoriola F., Molinuevo J.L., 1998. History of levodopa and dopamine agonists in Parkinson's disease treatment. Neurology, 50(6 Suppl 6): S2-S10.